Skip to main content

Table 2 Hypothesis testing for fixed effect model of digoxin pharmacokinetics

From: Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients

Fixed model OBJ LLD p-value
CL=θ1 −128.969   
θ1+θ2×CLcr −331.151 202.182 <0.001
θ1+θ2×BW −139.203 10.234 <0.002
θ1×θ2Ejection function (EF>41=1,EF<40=0) −129.247 0.278 N.S.
θ1×θ2Age (Age>65=0,Age<64=1) −131.508 2.539 N.S.
θ1×θ2Drug (0;Cocomitant adminstaraion,1;otherwise)    
Amiodarone −163.260 34.291 <0.001
Amlodipine −142.552 13.583 <0.001
Atorvastatin −135.985 7.016 <0.01
Azelnidipine −129.016 0.047 N.S.
Bisoprolol −145.971 17.002 <0.001
Carvedilol −134.190 5.221 <0.05
Nifedipine −129.355 0.386 N.S.
Spironolactone −132.177 3.208 N.S.
Tolvaptan −133.804 4.835 <0.05
Antiarrhythmic agent;Class I (Aprindine,Cibenzoline, Flecainide,Pilsicainde,Procainamide) −131.664 2.695 N.S.
Antiarrhythmic agent;Class IV (Bepridil,Diltiazem,Verapamil) −131.559 2.590 N.S.
  1. OBJ the minimum value of objective function, LLD-2 log-likefood difference, N.S not significant